The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients With High-Grade Glioma

Academic Radiology - United States
doi 10.1016/j.acra.2016.04.004
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Timing of Surgery and Bevacizumab Therapy in Neurosurgical Patients With Recurrent High Grade Glioma

Journal of Clinical Neuroscience
MedicineSurgeryNeurologyPhysiology
2015English

Antiangiogenic Therapy Using Bevacizumab in Recurrent High-Grade Glioma: Impact on Local Control and Patient Survival

Journal of Neurosurgery
SurgeryNeurology
2009English

Hypofractionated Stereotactic Radiation Therapy in Recurrent High-Grade Glioma: A New Challenge

Cancer Research and Treatment
Cancer ResearchOncology
2016English

Phase II Study of Bevacizumab and Vorinostat for Patients With Recurrent World Health Organization Grade 4 Malignant Glioma

Oncologist
Cancer ResearchMedicineOncology
2017English

Salvage Fractionated Stereotactic Re-Irradiation (FSRT) for Patients With Recurrent High Grade Gliomas Progressed After Bevacizumab Treatment

JHN Journal
2018English

The Information and Support Needs of Patients Diagnosed With High Grade Glioma

Patient Education and Counseling
Medicine
2010English

Use of Metformin and Survival of Patients With High-Grade Glioma

International Journal of Cancer
Cancer ResearchOncology
2018English

Echo-Planar MR Spectroscopic Imaging Pre and Post Radiation Therapy in Patients With High Grade Glioma

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2015English

P09.31 the Prognostic Value of Systemic Inflammatory Indices in Recurrent Glioma Treated With Bevacizumab

Neuro-Oncology
Cancer ResearchOncologyNeurology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy